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Mutations in the vacuolar protein sorting 35 homolog (VPS35) gene at the PARK17 locus, encoding a key com-
ponent of the retromer complex, were recently identified as a new cause of late-onset, autosomal dominant
Parkinson’s disease (PD). Here we explore the pathogenic consequences of PD-associated mutations in
VPS35 using a number of model systems. VPS35 exhibits a broad neuronal distribution throughout the rodent
brain, including within thenigrostriatal dopaminergic pathway. In thehuman brain, VPS35 protein levels and dis-
tribution are similar in tissues from control and PD subjects, and VPS35 is not associated with Lewy body path-
ology. The common D620N missense mutation in VPS35 does not compromise its protein stability or localization
to endosomal and lysosomal vesicles, or the vesicular sorting of the retromer cargo, sortilin, SorLA and cation-
independent mannose 6-phosphate receptor, in rodent primaryneurons or patient-derived humanfibroblasts. In
yeast we show that PD-linked VPS35 mutations are functional and can normally complementVPS35 null pheno-
types suggesting that they do not result in a loss-of-function. In rat primary cortical cultures the overexpression
of human VPS35 induces neuronal cell death and increases neuronal vulnerability to PD-relevant cellular stress.
In a novel viral-mediated gene transfer rat model, the expression of D620N VPS35 induces the marked degener-
ation of substantia nigra dopaminergic neurons and axonal pathology, a cardinal pathological hallmark of PD.
Collectively, thesestudies establish thatdominantVPS35mutations lead toneurodegeneration inPDconsistent
with a gain-of-function mechanism, and support a key role for VPS35 in the development of PD.
INTRODUCTION
Parkinson’s disease (PD) is a common progressive neurodegen-
erative movement disorder (1,2). The motor deficits of PD result
from the relatively selective degeneration of dopaminergic
neurons of the substantia nigra pars compacta. PD is character-
ized neuropathologically by the appearance of Lewy bodies in
surviving dopaminergic neurons that are enriched for fibrillar
a-synuclein (3). While the clinical and pathologic features of
PD are well-defined, the underlying cause of the disease
remains enigmatic. In 5–10% of cases, PD is inherited in a famil-
ial manner and disease-causing mutations have been identified in
at least eight genes (4,5).
Mutations in theVPS35 gene cause late-onset, autosomal dom-
inant familial PD (6,7). A single missense mutation, Asp620Asn
(D620N), was originally shown to segregate with PD in Swiss
and Austrian families, and has been identified in a number of
PD subjects and families worldwide (6–8). Additional rare
VPS35 variants (i.e. P316S, R524W, I560T, H599R and
M607V) may also be linked to PD although their pathogenicity
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Figure 1. Cellular distribution and levels of endogenous VPS35 in normal and pathological mammalian brain. (A) Subcellular fractionation of endogenous VPS35 in
mouse cerebral cortex. VPS35 is enriched in the microsomal (P3), synaptosomal (LP1) and synaptic vesicle (LP2) membrane fractions. Dynamin 1, TIM23,
a-synuclein and synaptophysin serve as markers for microsomes, mitochondria, synaptic vesicle cytosolic and synaptosomal/synaptic vesicle membranes, respect-
ively. Molecular mass is indicated in kDa. (B) Immunolabeling of endogenous VPS35 in the rat brain. VPS35 is detected in (i) pyramidal neurons of cortical layer III,
(ii) pyramidal neurons of the hippocampus (CA1 region), (iii) ventral midbrain, (iv) brainstem (superior olivary complex), (v) Purkinje neurons in the cerebellum
(granule cell layer, gcl; molecular layer, ml), (vi) deep cerebellar nuclei, and (vii) a sagittal section of rat brain (cerebral cortex, Ctx; hippocampal formation, Hip;
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remains unclear. VPS35 mutations are the second most common
cause of late-onset familial PD after LRRK2 mutations (9). The
neuropathological features of VPS35-linked PD are not yet
known since no mutation carriers have so far come to autopsy al-
though clinical and neuroimaging data suggest a classical disease
spectrum similar to idiopathic PD (6,7). The mechanism by which
dominantly inherited mutations in VPS35 precipitate PD is not
known.
Human VPS35 encodes a 796 amino acid protein that forms a
horseshoe-shaped a-helical solenoid (10,11). VPS35 is a key
subunit of the retromer complex involved in the retrieval and
sorting of transmembrane proteins from endosomes to the trans-
Golgi network (11,12). VPS35 interacts with VPS26A and
VPS29 to form a trimeric cargo recognition subcomplex that se-
lectively recognizes and binds to transmembrane cargo proteins
(13). This trimeric subcomplex associates with a sorting nexin
dimer required for its recruitment to endosomes (13). Retromer
substrates include intracellular receptors, such as the cation-inde-
pendent mannose 6-phosphate receptor (CI-M6PR), sortilin and
SorLA (11). The D620 residue of VPS35 is highly conserved
from yeast to humans suggesting a potentially important function
(6). It isconceivable that the familial D620N mutationmaydisrupt
the proper retromer-dependent trafficking of cargo proteins.
Aside from human genetic data (9), there are limited studies to
date exploring a role for VPS35 in PD. Here, we comprehensive-
ly explore the pathogenic effects of PD-linked VPS35mutations
by exploiting numerous model systems, including Saccharo-
myces cerevisiae, patient-derived fibroblasts, primary neuronal
cultures and viral-mediated gene transfer in rodents. Our data
demonstrate that PD-linked VPS35 mutations induce neuronal
degeneration most likely through a gain-of-function mechanism
and provide support for an important contribution of VPS35 to
the development of PD.
RESULTS
Distribution and levels of VPS35 in the normal
and pathological mammalian brain
To begin to understand how familial VPS35 mutations precipi-
tate neurodegeneration in PD, we investigated the normal
distribution of endogenous VPS35 in the mammalian brain. Sub-
cellular fractionation of mouse cerebral cortex reveals an enrich-
ment of VPS35 in microsomal vesicles (P3) and at lower levels in
crude synaptosomes (LP1) and synaptic vesicle membranes
(LP2) (Fig. 1A). Within the rat brain, VPS35 is broadly distrib-
uted to multiple neuronal populations including those within the
cerebral cortex, hippocampal formation, ventral midbrain,
brainstem and cerebellum (Fig. 1B). VPS35 is not particularly
enriched within neurons of the nigrostriatal dopaminergic
pathway, which selectively degenerate in PD (Fig. 1B).
However, confocal microscopic analyses reveal localization of
VPS35 to intracellular punctate structures within dopaminergic
neurons from rat primary midbrain cultures (Fig. 1C) or the intact
rat substantia nigra (Fig. 1D), consistent with the localization
of VPS35 to multiple vesicular compartments. Collectively,
VPS35 is selectively localized to neuronal vesicular compart-
ments throughout the rodent brain, including substantia nigra
dopaminergic neurons that selectively degenerate in PD.
To explore the relationship of VPS35 with PD, the distribution
and protein levels of VPS35 were assessed in postmortem human
brain tissue from normal control and PD/dementia with Lewy
bodies (DLB) subjects (refer to Table 1). VPS35 localizes equiva-
lently to pyramidal neurons throughout all layers of the cingulate
cortex of control and idiopathic PD/DLB subjects (Fig. 1E). The
steady-state levels of VPS35 are not significantly different in
caudate putamen extracts from a series of control and idiopathic
PD/DLB subjects (Fig. 1F, refer to Table 1) or in frontal cortex
extracts from an independent series of control, idiopathic PD or
G2019S LRRK2-linked PD subjects (Fig. 1G, refer to Table 2).
VPS35 fails to co-localize with a-synuclein-positive LB path-
ology within neurons located throughout the cingulate cortex of
idiopathic PD/DLB cases but localizes normally to intracellular
vesicles within LB-positive and LB-negative neurons from
control and PD/DLB brains (Fig. 1H). Our data demonstrate
that the neuronal distribution and levels of VPS35 protein are
not altered in the brains of PD or DLB subjects. PD-associated
mutations in the dominant gene product, LRRK2 (G2019S), do
not alter VPS35 levels within the human brain.
D620n VPS35 exhibits normal stability, vesicular
localization and sorting of retromer cargo
To explore the putative pathogenic effects of dominant familial
PD mutations in VPS35, we generated lentiviral vectors expres-
sing V5-tagged human VPS35 harboring the common D620N
mutation or wild-type (WT) protein. The D620N mutation
does not influence the steady-state levels of human VPS35
protein exogenously expressed in rat primary cortical neurons
(Fig. 2A). Furthermore, the D620N mutation fails to significantly
alter the vesicular localization of human VPS35 (Fig. 2B–C).
WT and D620N variants of VPS35 display a similar degree of
co-localization with multiple vesicular or membranous compart-
ments, including early (Rab5), late (Rab7) and recycling (Rab9)
endosomes, lysosomes (LAMP1) and the trans-Golgi network
cerebellum, Crb; deep cerebellar nuclei, DCN; caudate putamen, CPu; substantia nigra, SN. (C) Confocal microscopy analysis of rat primary midbrain cultures immu-
nolabeled with VPS35 and the dopaminergic marker, tyrosine hydroxylase (TH). Nuclei are labeled with DAPI. VPS35 localizes to punctate intracellular vesicular
structures within the soma and neuritic processes of TH-positive dopaminergic neurons. Scale bar: 10 mm. (D) Co-localization of endogenous VPS35 with
TH-positive dopaminergic neurons in the substantia nigra pars compacta of adult rats. Scale bar: 10 mm. (E) Immunolabeling of endogenous VPS35 in the human
cingulate cortex of control (1) and PD/DLB (3) subjects. Scale bar: 200 mm. High-magnification images of pyramidal neurons from cortical layer III are shown cor-
responding to the boxed area from control (2) and PD/DLB (4) brains. Scale bar: 50 mm. (F–G) Western blot analysis of soluble extracts from F human caudate
putamenof controland idiopathic PD/DLBsubjects, andGhumanfrontal cortexof control, idiopathicPD (PD) or G2019SLRRK2-linked PD subjects,with antibodies
to VPS35, and actin orb-tubulin as protein loading controls. Densitometric analysis of VPS35 normalized to actin orb-tubulin levels for individual subjects are shown
expressed as a percent of the mean of control subjects. Horizontal bars represent mean+SEM (n ¼ 4–5 subjects/group) for each subject group. Subjects without
VPS35 expression in F were excluded from the analysis (control ¼ 4 from 5; PD ¼ 5 from 7). ns, non-significant by one-way analysis of variance (ANOVA) with
Dunnett’s post hoc test. (H) Confocal microscopic analysis of VPS35 co-localization with Lewy bodies labeled with phospho-Ser129-a-synuclein in cortical
layer III neurons from a PD/DLB subject. Correlation coefficients (Rcoloc) and cytofluorograms indicate a lack of co-localization of VPS35 with Lewy bodies.
Scale bars: 20 mm (top panels) or 5 mm (bottom panels).
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(Giantin/GOLGB1 and Golgin/GOLGA4) in primary cortical
neurons (Fig. 2B–C). We do not observe any clear differences
in the subcellular distribution of VPS35-positive endosomal
and lysosomal vesicles between the WT and D620N variants
(Fig. 2B). In general, the D620N mutation does not compromise
the protein stability or vesicular localization of VPS35.
To determine whether the D620N mutation interferes with the
vesicular sorting of retromer cargo proteins, we assessed the ves-
icular localization of sortilin, SorLA and CI-M6PR. The
steady-state levels of sortilin and SorLA in cortical neurons
are not altered by the overexpression of human WT or D620N
VPS35 (Fig. 3A). Furthermore, the localization of endogenous
sortilin and SorLA to endosomes (Rab5, Rab7 and Rab9), lyso-
somes (LAMP1) and the Golgi network (GM130) in cortical
neurons are not significantly altered by the overexpression of
human WT or D620N VPS35 (Fig. 3B–C). The expression of
a third retromer cargo, CI-M6PR, could not be detected in cor-
tical neurons. Patient-derived skin fibroblasts were next used
to determine the effects of the D620N mutation on endogenous
VPS35. Primary fibroblasts derived from a single PD subject har-
boring the D620N mutation reveal normal steady-state levels of
endogenous VPS35 compared with WT control fibroblasts by
western blot analysis (Fig. 4A). The localization of the retromer
cargo, CI-M6PR, to endosomes (Rab5, Rab7 or Rab9), lyso-
somes (LAMP1) or the trans-Golgi network (Giantin) is not sig-
nificantly altered in D620N mutant fibroblasts compared with
WT control cells (Fig. 4B–C). The expression of additional ret-
romer cargo, sortilin and SorLA, could not be detected in
primary fibroblasts. Our data indicate that the D620N mutation
in VPS35 does not adversely influence the vesicular sorting of
retromer cargo proteins (i.e. sortilin, SorLA and CI-M6PR) in
primary neurons or patient-derived fibroblasts.
Familial PD mutations in VPS35 do not cause
a loss-of-function in yeast
To determine whether familial PD mutations in human VPS35 act
through a gain-of-function or a loss-of-function mechanism, we
employed the baker’s yeast S. cerevisiae for functional comple-
mentation studies. Yeast contains a highly conserved ortholog
of human VPS35 of 944 amino acids with54% protein similar-
ity (14). To initially identify phenotypes in yeast resulting from
VPS35 loss-of-function, haploid yeast cells harboring a deletion
of the endogenous VPS35 gene (Dvps35) were evaluated for
growth fitness on a number of carbon sources as well as sensitivity
to heavy metal exposure, based on phenotypic data deposited in
the Saccharomyces Genome Database (www.yeastgenome.org).
VPS35 null yeast exhibit increased resistance to growth on
media containing nickel (Ni2+), increased sensitivity to
cadmium (Cd2+) but no difference to manganese (Mn2+) com-
pared with a WT yeast strain (Fig. 5A–D). VPS35 null yeast
further display normal growth on media containing fermentable
carbon sources (dextrose orgalactose)but reduced growth on non-
fermentable carbon sources (glycerol and ethanol) compared with
WT yeast (Fig. 5A–D). Non-fermentable carbon sources require
mitochondrial oxidative phosphorylation for their utilization sug-
gesting that deletion ofVPS35 in yeast may impair mitochondrial
respiration.
The overexpression of V5-tagged human VPS35 variants
[WT, D620N and P316S, a putative pathogenic mutation identi-
fied in a US family (6)] from a low-copy galactose-inducible
vector (p416GAL1) is unable to robustly complement the
growth phenotypes of Dvps35 yeast on media containing Ni2+
or Cd2+ (Fig. 5F). However, we observe a rather modest
rescue of the Cd2+-induced growth deficit inDvps35 yeast by ex-
pression of D620N VPS35, suggesting a partial complementa-
tion compared with WT or P316S VPS35 (Fig. 5F). Notably,
the inducible overexpression of human VPS35 variants in WT
or Dvps35 yeast does not generally influence cell growth and
therefore VPS35 variants are not intrinsically toxic to yeast
(Fig. 5F). Our data suggest that human VPS35 lacks functional
conservation with yeast VPS35, at least in regulating the suscep-
tibility to heavy metal exposure.
Table 1. Clinical details of human brain tissue from JHMI
Subject Case # Gender Age
(years)
PMD (h) Region Use
Control 1683 F 91 8 CING IHC
Control 1881 F 48 12 CING IHC
Control 993 M 66 12 PUT WB
Control 1361 F 49 15 PUT WB
Control 1613 M 74 4 PUT WB
Control 1683 F 91 8 PUT WB
Control 2052 M 79 16 PUT WB
PD 1606 F 45 12 CING IHC
PD/AD/LB variant 1686 F 73 18 CING IHC
DLB/AD 1699 F 89 7 CING IHC
PD/AD/DLB 1864 M 63 24 CING IHC
PD/DLB 1828 F 86 16 PUT WB
PD 1938 M 70 26 PUT WB
PD/DLB 1981 F 88 19.5 PUT WB
PD/DLB 2003 F 95 12 PUT WB
PD/dementia 2019 M 83 16.5 PUT WB
PD/dementia 2053 M 75 6 PUT WB
PD/dementia 2071 F 85 9 PUT WB
AD, Alzheimer’s disease; CING, cingulate cortex; DLB, dementia with Lewy
bodies; LB, Lewy body; IHC, immunohistochemistry; PMD, postmortem delay;
PUT, caudate putamen; WB, western blot.
Table 2. Clinical details of human frontal cortex tissue used for biochemical
analysis (from QSBB)
Subject Gender Age (years) PMD (h) Pathology
Control 1 F 85 37 N/A
Control 2 M 93 112 N/A
Control 3 F 91 98.5 N/A
Control 4 M 87 36 N/A
iPD 1 F 69 52.5 Limbic
iPD 2 M 70 61.2 Limbic
iPD 3 F 87 47.45 Limbic
iPD 4 M 75 48 Limbic
G2019S 1 F 80 44.4 Limbic
G2019S 2 F 81 15 Limbic
G2019S 3 F 84 32.2 Limbic
G2019S 4 F 72 24.55 Limbic
iPD, idiopathic Parkinson’s disease; Limbic, limbic subtype of Lewy body
pathology according to McKeith consensus criteria for the classification of DLB;
N/A, non-applicable; PMD, postmortem delay.
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As an alternative strategy, mutations analogous to the familial
PD variants, D686N (D620N in hVPS35) and P299S (P316S in
hVPS35), were introduced into yeast VPS35 in low-copy
galactose-inducible expression vectors to assess the functional
effects of these analogous PD-like mutations. The D620 and
P316 residues in VPS35 are highly conserved from yeast to
humans (Fig. 5E). The overexpression of HA-tagged yeast
VPS35 variants (WT, D686N and P299S) are able to equivalently
and robustly rescue the growth phenotype of Dvps35 yeast on
media containing Ni2+ or Cd2+, whereas the overexpression of
yeast VPS35 variants does not influence the normal growth of
WT or Dvps35 yeast strains (Fig. 5F). Western blot analysis
reveals equivalent levels of expression of human and yeast
VPS35 variants in yeast following galactose induction
Figure 2. Normal steady-state levels and vesicular localization of VPS35D620N in cortical neurons. (A) Western blot analysis of soluble extracts from primary cortical
neurons infected with lentiviral vectors expressing V5-tagged human VPS35 (WT or D620N) or control virus with anti-V5 or b-tubulin antibodies. Densitometric
analysis of human VPS35 normalized to b-tubulin levels indicates the equivalent expression of WT and D620N variants (mean+SEM, n ¼ 4 experiments). n.s.,
non-significant by unpaired, two-tailed Student’s t-test. (B) Representative confocal microscopic images of primary cortical neurons co-labeled for WT or D620N
human VPS35 (V5) and RFP-Rab5, GFP-Rab7, RFP-LAMP1 or trans-Golgi protein Giantin, and DAPI. Inset indicates enlarged boxed area in merged images. Cyto-
fluorograms and correlation coefficients (Rcoloc, mean+SEM, n ≥ 5 neurons) indicate the degree of co-localization of fluorescence signals for V5 and each marker.
Scale bars: 10 mm. (C) Graph showing co-localization coefficients (mean+SEM, n ≥ 5 neurons/group) of WT or D620N VPS35 with each vesicular marker in cor-
tical neurons. n.s., non-significant by unpaired, two-tailed Student’s t-test as indicated.
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Figure 3. Protein levels and vesicular sorting of the retromer cargo sortilin and SorLA are not altered by VPS35D620N expression in primary cortical neurons. (A) Western
blot analysis of soluble extracts from primary cortical neurons infected with lentiviral vectors expressing V5-tagged human VPS35 (WT or D620N) or a control virus,
with antibodies to sortilin, SorLA and V5 or b-tubulin as a protein loading control. Graphs indicate densitometric analysis of sortilin or SorLA normalized tob-tubulin
levels and expressed as percent of the VPS35WT condition (mean+SEM, n ¼ 4 experiments). (B) Representative confocal microscopic images of primary cortical
neurons co-labeled for human VPS35 (V5), sortilin or SorLA and each vesicular marker (GFP-Rab7 or RFP-LAMP1), and DAPI. Inset indicates enlarged boxed area
in merged images. Cytofluorograms and correlation coefficients (Rcoloc, mean+SEM, n ≥ 7 neurons) indicate the degree of co-localization of fluorescence signals
for sortilin or SorLA and each vesicular marker. Scale bars: 10 mm. (C) Graph showing co-localization coefficients (mean+SEM, n ≥ 7 neurons/group) of sortilin
(upper) or SorLA (lower) with each vesicular marker (RFP-Rab5, GFP-Rab7, GFP-Rab9, RFP-LAMP1 or Golgi protein GM130) in cortical neurons expressing
human VPS35 (WT or D620N) or a control vector. n.s., non-significant by one-way ANOVA with Newman–Keuls post hoc analysis.
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Figure 4. Normal VPS35 Levels and Vesicular Sorting of the Retromer Cargo CI-M6PR in Primary Human Fibroblasts Derived from a D620N Mutant PD Subject.
(A) Westernblotanalysisof1%Triton-soluble (T-sol.) and Triton-insoluble (T-insol.) fractions ofprimaryfibroblasts derived froma Parkinson’s diseasesubject harboring
the D620N VPS35 mutation (PD) and a healthy control (Ctl). Blots are probed with antibodies to VPS35 and b-tubulin as a protein loading control. Molecular mass
is indicated in kDa. (B) Representative confocal microscopic images and cytofluorograms of human primary fibroblasts (control or D620N) co-labeled for
cation-independent mannose-6-phosphate receptor (CI-M6PR) and vesicular markers (RFP-Rab5, GFP-Rab7, GFP-Rab9, RFP-LAMP1 or trans-Golgi protein
Giantin). Enlarged boxed areas of merged images are shown. Scale bar: 10 mm. (C) Graph indicates the co-localization coefficients (mean+SEM, n ≥ 5 cells) of
CI-M6PR with each vesicular marker in primary fibroblasts from control or D620N PD subjects. n.s., non-significant by unpaired, two-tailed Student’s t-test, as indicated.
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Figure 5. Analogous PD-like mutations in yeast VPS35 can functionally complement growth phenotypes in VPS35 null yeast cells. (A–D) Haploid yeast cells
(BY4741, MATa), either wild-type (WT) or with a deletion of VPS35 (vps35D), were spotted onto YP(Dex) rich media containing different concentrations of
(A) nickel (Ni2+), (C) cadmium (Cd2+) or (D) manganese (Mn2+), or YP media containing (B) non-fermentable carbon sources, glycerol (Gly) or ethanol
(EtOH), and grown for 2–3 days at 308C. Shown are 5-fold serial dilutions (from top to bottom) starting with equal numbers of cells. (E) Protein sequence alignment
of VPS35 in the region encompassing the human P316 and D620 residues across several model species, indicating the high conservation of these two residues. (F) WT
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(Fig. 5G). Collectively, our data indicate that analogous PD-like
mutations in yeast VPS35 (P299S and D686N), that are highly
conserved with human VPS35 (P316S and D620N) (Fig. 5E),
are fully functional compared with the WT protein, suggesting
that these dominantly inherited mutations do not act through a
loss-of-function mechanism. Our data support instead a gain-
of-function mechanism for the pathogenic actions of familial
PD mutations in VPS35.
Human VPS35 induces neuronal cell death and increases
neuronal vulnerability to stress
To explore the putative pathogenic effects of familial PD muta-
tions in VPS35, human VPS35 variants (WT and D620N) were
overexpressed in neuronal cultures to model gain-of-function
effects. We evaluated the viability of rat primary cortical
neurons following infection with lentiviral vectors expressing
human VPS35 variants or GFP as a negative control. Lentiviral
infection of cortical cultures at days-in vitro (DIV) 3 results in the
efficient and long-term transduction of the majority of cortical
neurons as indicated by labeling of cultures for V5-tagged
VPS35 or GFP (Fig. 6A). The overexpression of WT or
D620N VPS35 in cortical neurons up to DIV 14 significantly
increases apoptotic neuronal cell death (Fig. 6B) and reduces
neuronal viability (Fig. 6C) compared to infection with control
lentiviral vectors (empty or GFP). Furthermore, the transient
overexpression of human WT or D620N VPS35 in cortical
neurons significantly impairs neurite outgrowth (Fig. 6D–E).
Notably, no significant differences are observed between WT
and D620N variants upon these VPS35-dependent neuronal phe-
notypes.
To further explore and compare the impact of human WT and
D620N VPS35 on neuronal vulnerability, we assessed the contri-
bution of VPS35 to neuronal cell death induced by various cellu-
lar toxins or stressors implicated in the pathogenesis of PD (5).
The lentiviral-mediated overexpression of human WT or
D620N VPS35 significantly sensitizes to neuronal cell death
induced by exposure of primary cortical cultures to the mito-
chondrial Complex-I inhibitors, MPP+ (250 mM) and rotenone
(500 nM), and to oxidative stress induced by hydrogen peroxide
(25 mM) (Fig. 6F). Human VPS35 variants also increase the
vulnerability of cortical neurons to proteosomal inhibition
induced by MG132 (10 mM) although to a smaller extent
(Fig. 6G). VPS35 overexpression fails to increase neuronal vul-
nerability to the autophagy/lysosomal inhibitor, bafilomycin A1
(60 nM), or to disruption of ER-Golgi transport induced by bre-
feldin A (250 mM) (Fig. 6G), thereby supporting a specific inter-
action of VPS35 with neuronal susceptibility to mitochondrial
toxins, oxidative stress and proteasomal inhibition. No signifi-
cant differences are observed between the WT and D620N var-
iants of VPS35 in their capacity to increase neuronal
vulnerability to toxins thereby arguing against a loss-of-function
mechanism for familial PD mutations. Taken together, our data
demonstrate that the overexpression of human VPS35 induces
neuronal cell death, impaired neurite outgrowth and increases
neuronal vulnerability to cellular stress most likely through a
gain-of-function mechanism. However, pathogenic phenotypes
induced in primary neuronal culture models do not obviously
permit the discrimination between the effects of WT and
D620N VPS35, an observation that is similar for dominantly
inherited mutations in a-synuclein (15).
Viral-mediated expression of D620N VPS35 induces
dopaminergic neurodegeneration in rats
To explore the pathogenic effects of dominant VPS35 mutations
in vivo, human WT and D620N VPS35 were overexpressed in
substantia nigra dopaminergic neurons of rats to develop an
animal model of VPS35-associated PD. Adeno-associated viral
vectors (AAV2/6) expressing V5-tagged human VPS35 (WT or
D620N) were delivered to the substantia nigra pars compacta of
adult rats by unilateral stereotactic injection. At 12 weeks postin-
jection of virus, we observe robust, widespread and equivalent ex-
pression of WT and D620N VPS35 throughout the injected
substantia nigra with substantial co-localization with tyrosine
hydroxylase (TH)-positive dopaminergic neurons (Fig. 7A–B).
To assess whether human WT or D620N VPS35 induces dopa-
minergic neurodegeneration, we quantified the number of
TH-positive dopaminergic and total Nissl-positive neurons in
the substantia nigra pars compacta of injected animals using un-
biased stereological methodology. The expression of D620N
VPS35 produces a significant loss of nigral dopaminergic
neurons (32.02+8.6% loss) in the injected nigra compared
with a control virus (5.9+3.2% loss) (Fig. 7C). The expression
of WT VPS35 induces an intermediate level of dopaminergic
neuronal loss (24.6+7.4% loss) in the injected nigra compared
with the control condition (Fig. 7C). A parallel loss of Nissl-
positive neurons is observed in the injected substantia nigra rela-
tive to the non-injected nigra with each virus (D620N, 23.23+
8.2%; WT, 17.93+5.1%; control, 6.5+1.1%) indicating dopa-
minergic neurodegeneration rather than a loss of TH expression or
dopaminergic phenotype (Fig. 7C). A corresponding loss of
TH-positive dopaminergic nerve terminals (D620N, 14.6+
4.4%; WT, 9.1+5.5%; control, 5.3+1.3%) is also observed
in the ipsilateral striatum compared with the contralateral striatum
of rats injected with each virus (Fig. 7D–E). To determine
whether VPS35-induced dopaminergic neuronal loss culminates
in motoric deficits in rats, we employed the cylinder test to
measure contralateral forelimb use which is controlled by the ip-
silateral substantia nigra (16). However, we observe no significant
impairment ofcontralateral forelimbuse inducedby the ipsilateral
expression of human WT or D620N VPS35 at 7, 9 and 11 weeks
postinjection of virus (Fig. 7F).
To confirm the equivalent expression of human VPS35 var-
iants in injected animals, we conducted western blot analysis
of ventral midbrain extracts at 12 weeks postinjection. Human
or vps35D yeast strains were transformed with galactose-inducible low-copy expression vectors containing HA-tagged yeast VPS35 (WT, D686N or P299S) or
V5-tagged human VPS35 (WT, D620N or P316S) variants, or with an empty vector (p416GAL1). Equivalent numbers of cells were spotted as five-fold serial dilutions
(from left to right) onto complete synthetic media lacking uracil (CSM) and containing galactose as the sole carbon source with or without additional Ni2+ (2.5 mM) or
Cd2+ (12 mM), as indicated. (G) Western blot analysis of soluble extracts from WT yeast cells transformed with yeast or human VPS35 variants following growth on
CSM-URA media containing galactose to induce VPS35 expression. VPS35 is detected using anti-HA or anti-V5 antibodies with an antibody to 3-phosphoglycerate
kinase (PGK) used as a protein loading control.
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V5-tagged WT and D620N VPS35 are detected at equivalent
levels in the injected ventral midbrain of rats (Fig. 7G–H). An
antibody that detects both rat and human VPS35 fails to demon-
strate the overexpression of human VPS35 relative to endogen-
ous VPS35 in ventral midbrain extracts suggesting either a
dilution effect of the transgene in this brain region or a potential
lowering of endogenous VPS35 levels in response to human
VPS35 expression (Fig. 7G). Western blot analysis further indi-
cates a reduction of TH levels in the ventral midbrain induced by
WT and D620N VPS35 expression (Fig. 7G–H), which corre-
lates with the observed dopaminergic neuronal loss (Fig. 7C).
Consistent with our data in neuronal cultures (Fig. 3A), we do
not observe alterations in the steady-state levels of sortilin or
SorLA resulting from the expression of human VPS35 variants
in the ventral midbrain of rats (Fig. 7G–H). It was not possible
to reliably detect CI-M6PR in these ventral midbrain extracts
with currently available antibodies. Instead, the lysosomal pro-
tease cathepsin D, a soluble ligand of CI-M6PR (17), was
assessed. However, the expression of human VPS35 variants
does not alter the steady-state levels or processing of cathepsin
D in the ventral midbrain (Fig. 7G–H).
The neuropathological spectrum of PD brains harboring
VPS35 mutations is uncertain since no mutation carriers have
yet come to autopsy (9). To determine the pathological conse-
quences ofVPS35mutations in vivo, we assessed the distribution
of a number of classical markers of neurodegeneration in the
Figure 6. Overexpression of human VPS35 induces neuronal cell death, impairs neurite outgrowth and increases neuronal vulnerability to cellular stress. (A) Rep-
resentative immunofluorescent images of primary cortical neurons at DIV 14 infected with GFP or VPS35WT lentivirus (green) and co-labeling of apoptotic (TUNEL-
positive, red) or total (DAPI-positive, cyan) nuclei to assess neuronal cell death. Scale bar: 50 mm. (B) Cortical neurons infected with lentiviral vectors expressing GFP
or human VPS35 variants were assessed for apoptotic cell death by quantifying the number of TUNEL-positive neurons as a percent of total neurons (DAPI-positive
nuclei) for each condition (mean+SEM, n ¼ 5 independent cultures). (C) Neuronal viability was assessed in cortical cultures infected with lentiviral vectors at DIV
14 by counting the average number of neurons (DAPI-positive nuclei) for each condition, and expressed as a percent of an empty control virus (mean+SEM, n ¼ 5
independent cultures). (D) Representative fluorescent microscopic images of cortical neurons at DIV 7 co-labeled with V5-tagged human VPS35 (WT or D620N) and
GFP. GFP images were pseudocolored with ICA to identify neuronal soma (arrowhead) and axonal processes (arrows) for neurite length measurements. Scale bar:
200 mm. (E) Quantitation of axonal process length from GFP-positive neurons expressing human VPS35 (WT or D620N) compared with control neurons (empty
vector). Bars represent neurite length (mean+SEM, n ¼ 5 independent cultures) from 170–189 neurons. (F) Primary cortical neurons infected with lentiviral
vectors expressing human VPS35 (WT or D620N) or GFP were treated at DIV 14 with cellular toxins (MPP+, rotenone or H2O2) for 24 h and assessed by alamarBlue
cell viability assay. Bars represent cell viability expressed as a percent of untreated cultures for each condition (mean+SEM, n ≥ 3 independent cultures). (G) Cor-
tical neurons infected with lentiviral vectors as in F were treated with cellular toxins (MG132, BrefeldinA or Bafilomycin A1) for 24 h prior to cell viability assays. Cell
viability relative to untreated cultures is shown (mean+SEM, n ≥ 3 independent cultures). Data were analyzed by one-way ANOVA with Newman–Keuls post hoc
analysis, as indicated (∗P,0.05, ∗∗P,0.01 or ∗∗∗P,0.001). n.s., non-significant.
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substantia nigra pars compacta of rats expressing WT or D620N
VPS35. At 12 weeks postinjection, we do not observe alterations
in the distribution of total or phosphorylated (Ser129)
a-synuclein (Fig. 8), a major component of Lewy body path-
ology in PD and other a-synucleinopathies (3,18), following
human VPS35 expression. Similarly, we do not detect changes
in total (Tau5) or hyperphosphorylated (PHF-1) forms of the
microtubule-associated protein tau (Fig. 8), a protein involved
in neurodegenerative tauopathies (19) and implicated in PD
(20,21). Alterations in phosphorylated neurofilaments (SMI31
and SMI312), a marker of axonal processes and terminals, or
p62/sequestosome 1, a marker of autophagic/lysosomal
vacuoles, are also not detected in the injected substantia nigra
(Fig. 8). The expression of human WT and D620N VPS35
results in the accumulation of spherical inclusions containing
amyloid precursor protein (APP) within axonal processes
(Fig. 8), a sensitive marker of axonal damage (22). Gliosis typic-
ally accompanies neuronal degeneration in PD and other neuro-
degenerative diseases. However, astrogliosis (GFAP) and
microgliosis (Iba1) are not generally observed in the substantia
nigra of rats at 12 weeks postinjection of virus (Fig. 8).
The accumulation of APP-positive axonal inclusions suggests
that human VPS35 expression may also promote axonal degener-
ation. Substantia nigra sections from injected rats at 12 weeks
were stained with silver which specifically labels components of
degenerating neurons, including lysosomes, axonal processes
and their terminals (23,24). The expression of D620N VPS35
induces a significant increase in the appearance of silver-positive
degenerating axonal processes and nerve terminals compared
with WT VPS35 or a control virus (Fig. 9). Collectively, our
data reveal the marked degeneration of substantia nigra dopamin-
ergic neurons and axonal pathology induced by the expression of
the familial D620N mutation of VPS35 in the adult rat brain,
which recapitulates a cardinal pathological hallmark of PD.
DISCUSSION
Mutations in the VPS35 gene cause late-onset, autosomal domin-
ant PD with the D620N mutation representing a common cause of
VPS35-linked disease (6–9). The mechanism(s) through which
dominant VPS35 mutations precipitate neurodegeneration in PD
are not known, and the neuropathological consequences of
VPS35 mutations in PD subjects are poorly defined at present.
Here, we present multiple lines of evidence demonstrating that
the dominant D620N mutation in VPS35 is capable of inducing
dopaminergic neuronal degeneration most likely through a
gain-of-function mechanism. First, familial mutations do not
compromise VPS35 protein stability or its normal localization
to endosomes and lysosomes. Furthermore, the vesicular sorting
of retromer cargo, sortilin, SorLA and CI-M6PR, which depend
on VPS35 as a key component of the retromer substrate recogni-
tion subcomplex (11), is not altered by mutations in VPS35.
Second, the equivalent PD-like mutation in yeast VPS35
(D686N) is fully functional compared with the WT yeast
protein in complementing growth phenotypes in VPS35 null
yeast. The D620 residue and the VPS35 protein sequence in
general are highly conserved throughout evolution. Therefore,
our data suggest that the D620N mutation does not result in a
loss-of-function. Third, the lentiviral-mediated overexpression
of human VPS35 variants impairs neuronal integrity and viability,
and increases the vulnerability of neurons to PD-relevant cellular
stressors, including mitochondrial Complex-I inhibition, oxida-
tive stress and proteasomal inhibition (5). Fourth, the AAV-
mediated expression of human D620N VPS35 in the substantia
nigra of adult rats induces marked dopaminergic neuronal degen-
eration with an intermediate effect of human WT VPS35 com-
pared with a control virus. Therefore, the D620N mutation in
VPS35 recapitulates a cardinal pathological hallmark of PD in a
novel animal model. Taken together, our data demonstrate that
the PD-associated dominant D620N mutation in VPS35 is able
to induce neuronal degeneration most likely through a gain-of-
function mechanism, thereby establishing an important contribu-
tion of VPS35 to the development of PD.
The distinct absence of truncation, rearrangement or deletion
mutations in VPS35 identified so far across multiple PD cohorts
worldwide, together with the dominant inheritance pattern of
the common D620N mutation, suggests that mutations are not
likely to act through a loss-of-function mechanism. Thus,
VPS35 mutations most likely operate through a gain-of-function
mechanism. Consistent with such a mechanism, the D620N muta-
tion does not compromise the steady-state levels of VPS35 and its
normal localization to early and late endosomes and lysosomes
withincorticalneurons, suggesting the absence of major structural
perturbations toVPS35.Arecent studysuggestsa redistributionof
early and late endosomes containing D620N VPS35 to the peri-
nuclear region in A431 cells (25). However, our data do not indi-
cate a redistribution of D620N VPS35-positive vesicles in cortical
neurons. We further demonstrate that the ectopic expression
of D620N VPS35 in rodent cortical neurons or endogenous
D620N VPS35 in human fibroblasts does not influence the
levels or vesicular sorting of well-known retromer cargo proteins,
such as sortilin, SorLA and CI-M6PR. Thus, the D620N mutation
does not apparently influence the overall substrate recognition or
binding of retromer cargo to VPS35. A recent study suggests that
the expression of D620N VPS35 causes a defect in the vesicular
trafficking and processing of the lysosomal protease cathepsin
D, a soluble ligand of CI-M6PR (25). Whether the defective traf-
ficking of cathepsin D induced by D620N VPS35 also occurs in
neurons and promotes neuronal degeneration in PD remains
unclear. However, we failed to observe alterations in the levels
and processing of cathepsin D in the ventral midbrain of rats
expressing human D620N VPS35. Our findings suggest that fa-
milial mutations in VPS35 do not lead to an overall disruption
of VPS35 protein structure and retromer-dependent protein
sorting in neurons, implying that mutations may instead exert
subtle or selective effects on specific retromer cargo and/or in spe-
cific cell types.
Recent studies have suggested that the D620N mutation might
compromise neuroprotective effects mediated by human VPS35
overexpression, consistent with a loss-of-function mechanism.
WT VPS35 was recently shown to protect against neuronal tox-
icity induced by the mitochondrial Complex-I inhibitor, MPP+
(26), as well as against G2019S LRRK2 overexpression or
RAB7L1 deficiency (27), two models relevant to familial PD. In
this scenario, VPS35 haploinsufficiency would be sufficient to
induce neurodegeneration related to PD. While the homozygous
deletion of VPS35 in mice results in early embryonic lethality,
VPS35 haploinsufficiency has been reported to enhance Alzhei-
mer’s disease (AD)-like neuropathology in a mouse model of
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Figure 7. Dopaminergic neuronal degeneration induced by AAV2/6-mediated expression of D620N VPS35 in the substantia nigra of adult rats. (A) Photomicrographs
showing immunofluorescent co-labeling of substantia nigra with anti-V5 and anti-TH antibodies indicating the equivalent expression of V5-tagged human VPS35WT
and VPS35D620N proteins within dopaminergic neurons at 12 weeks following stereotactic injection of AAV2/6 vectors. Scale bar: 200 mm. (B) Representative photo-
micrographs of anti-V5 and anti-TH immunohistochemical analysis in adjacent sections of rat substantia nigra at 12 weeks following the stereotactic injection of
AAV2/6 vectors expressing human VPS35WT and VPS35D620N or a control vector. V5 labeling in the substantia nigra is accompanied by a decrease in TH
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AD (28). Whether PD-related neuropathology or motor deficits
occur in mice heterozygous for VPS35 is not yet known (28).
We employed yeast as a model to demonstrate that mutations
equivalent to D620N in a highly conserved yeast ortholog of
VPS35 (i.e. D686N) can normally complement growth pheno-
types inDvps35 yeast thereby indicating that the D N substitu-
tion at this highly conserved residue does not compromise VPS35
function. In contrast to prior studies (26,27), we demonstrate that
the overexpression of human WT VPS35 in primary cortical
neurons is detrimental rather than neuroprotective and leads to
neuronal cell death and impaired neurite outgrowth. Moreover,
VPS35 overexpression dramatically increased neuronal vulner-
ability to PD-relevant cellular stressors, including the mitochon-
drial Complex-I inhibitors MPP+ and rotenone, rather than
eliciting neuroprotection as previously suggested (26). Impor-
tantly, the D620N mutation did not impair VPS35-induced neur-
onal toxicity or increased vulnerability which would be
inconsistent with a loss-of-function mechanism. In our neuronal
culture model we were not able to discern obvious differences
between WT and D620N VPS35 in their capacity to induce neur-
onal damage. In contrast, the viral-mediated overexpression of
human D620N VPS35 in the rat substantia nigra induced dopa-
minergic neuronal degeneration and axonal damage, whereas
WT VPS35 produced an intermediate level of neuropathology.
Therefore, the pathological effects of the D620N mutation can
be unmasked given the proper cellular context, and supports a
gain-of-function mechanism for the actions of PD-associated
VPS35 mutations.
We have developed a novel animal model ofVPS35-associated
PD that recapitulates one of the cardinal pathological features of
disease, i.e. nigral dopaminergic neuronal loss. The degeneration
of dopaminergic neurons in adult rats induced by D620N VPS35
was pronounced at 12 weeks after viral delivery. Whether this
model recapitulates the progressive nature of neuronal loss in
PD is not yet clear. It will be important in future studies to deter-
mine whether varying the dosage or time course of transgene ex-
pression would be sufficient to further enhance nigral neuronal
degeneration, and potentially exacerbate differences between
WT and D620N VPS35. The expression of D620N VPS35 in
the rat substantia nigra does not recapitulate other aspects of
PD-related neuropathology such as the formation of a-synu-
clein-positive Lewy pathology, tau-positive neurofibrillary
tangles or gliosis. However, we do not yet know the full repertoire
of pathological inclusions or aggregates in brains from PD sub-
jects with VPS35 mutations. Our in vivo studies formally prove
that the dominant D620N mutation inVPS35can induce dopamin-
ergic neuronal loss, a key pathological feature of familial and
idiopathic PD. This new rodent model of VPS35-associated PD
will prove useful for uncovering the molecular mechanisms of
VPS35-dependent neurodegeneration and for the identification
of disease-modifying therapeutic agents.
MATERIALS AND METHODS
Animals
Rats were maintained in a pathogen-free barrier facility and
exposed to a 12 h light/dark cycle with food and water provided
ad libitum. Pregnant female Sprague-Dawley rats were obtained
from Charles River Laboratories (L’Arbresle Cedex, France)
and resulting P1 rats were used for preparation of primary neur-
onal cultures. All animal experiments were approved by the
SCAV (Service de la consommation et des affaires veterinaires)
in the Canton de Vaud, Switzerland (Animal authorization No.
2572), and conducted in strict accordance with the European
Union directive (2010/63/EU) for the care and use of laboratory
animals.
Expression plasmids and antibodies
A pLenti6/V5/DEST mammalian expression plasmid contain-
ing full-length human VPS35 with a C-terminal V5 tag was
obtained from Addgene [#21691, (29)]. D620N and P316S
mutations were introduced by PCR-mediated site-directed mu-
tagenesis and sequenced to confirm their integrity. V5-tagged
VPS35 cDNAs (WT, D620N or P316S) were amplified by
PCR from a pLenti6-VPS35 vector, and cloned into a directional
pENTR/D-TOPO entry vector (Invitrogen), sequenced to
confirm their integrity, and subjected to recombination with a
Gateway-compatible lentiviral vector, pSIN-PGK-WHV (30)
(kindly provided by Dr. Nicole Deglon, CHUV, Switzerland).
As plasmid controls, pcDNA3.1 (Invitrogen), pEGFP-N1 (Clon-
tech) and pDsRed-Max-N1 (Addgene #21718) were employed.
Expression plasmids containing human RFP-Rab5A (#14437),
human GFP-Rab7A (#12605), human GFP-Rab9A (#12663)
and rat LAMP1-RFP (#1817) were obtained from Addgene.
The following primary antibodies were used: rabbit VPS35
(ABT48, Millipore), mouse anti-V5 and anti-V5-peroxidase
(Invitrogen), mouse anti-b-tubulin (clone TUB 2.1, Sigma-
Aldrich), rabbit anti-tyrosine hydroxylase (TH, NB300-109,
Novus Biologicals), mouse anti-TH (clone TH-2, Sigma-
Aldrich), mouse anti-HA-peroxidase (clone 12CA5, Roche),
mouse anti-PGK (clone 22C5D8, Invitrogen), rabbit anti-
Dynamin-1 (PA1-660, Thermo Scientific), mouse anti-TIM23
immunostaining. Scale bar: 1 mm. (C) Stereological analysis of TH-positive dopaminergic or total Nissl-positive neurons in the substantia nigra expressed as percent
cell loss relative to the contralateral uninjected nigra. Bars represent mean+SEM (n ¼ 6 animals/group). ∗P,0.05 by one-way ANOVA with Dunnett’s post hoc
analysis. n.s., non-significant. (D) Representative photomicrographs of immunostaining for TH-positive nerve terminal in the striatum at 12 weeks following AAV2/6
delivery. Scale bar: 1 mm. (E) Quantitation of optical density of TH immunostaining in the striatum. Data are expressed as percent loss of TH-positive fibers relative to
the contralateral uninjected side. Bars represent the mean+SEM (n ≥ 4 animals/group). Data were assessed by one-way ANOVA with Dunnett’s post hoc analysis.
(F) Cylinder asymmetry test performed at 7, 9 and 11 weeks postsurgery assessing forelimb contacts with the cylinder wall over a 5 min period. Forelimb use contra-
lateral to the injected nigra is expressed as a percent of total forelimb contacts (left + right) on the cylinder wall. Dashed line indicates the expected forelimb usage
under normal conditions. Bars represent mean+SEM (n ¼ 8 animals/group). Data were assessed by one-way ANOVA with Newman–Keuls post hoc analysis. (G)
Western blot analysis of soluble extracts from ventral midbrain at 12 weeks following stereotactic injection of rats with AAV2/6 vectors, separated into ipsilateral (+)
and contralateral (2) hemispheres. Blots were probed with antibodies to V5, VPS35, TH, sortilin, SorLA and cathepsin D, with b-tubulin as a loading control. Mo-
lecular masses are indicated in kDa. (H) Densitometric analysis of V5, TH, sortilin, SorLA or cathepsin D levels normalized to b-tubulin levels on blots containing
ventral midbrain extracts. Bars represent mean+SEM (n ¼ 3–4 animals/group). Data were analyzed by one-way ANOVA with Newman–Keuls post hoc analysis
for multiple comparisons, or by unpaired, two-tailed Student’s t-test for pair-wise comparisons, as indicated. n.s., non-significant.
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Figure 8. AAV2/6-mediated expression of human VPS35 in the rat substantia nigra induces axonal pathology. Immunohistochemical analysis of substantia nigra at 12
weeks following the stereotactic injection of AAV2/6 vectors expressing human VPS35WT and VPS35D620N or a control vector. Antibodies detecting total
a-synuclein, a-synuclein phosphorylated at Ser129 (P-a-synuclein), total tau (Tau5), tau phosphorylated at Ser396 and Ser404 (PHF-1), APP isoforms, phosphory-
lated neurofilament H (SMI31), phosphorylated neurofilament M/H (SMI312), autophagy substrate p62/sequestosome 1, GFAP and Iba1 were employed. Represen-
tativephotomicrographsare taken from the injected substantia nigra as indicated in the schematicdiagram.Scale bar: 50 mm. Macroscopic imagesof GFAPand Iba1 in
the injected and non-injected substantia nigra are shown for comparison. Boxes indicate the region used for high-power images of the injected substantia nigra. Scale
bar: 50 mm.
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(clone 32, BD Biosciences), mouse anti-a-synuclein (clone 42,
BD Biosciences), mouse anti-pSer129 a-synuclein (Wako),
mouse anti-GM130 (clone 35, BD Biosciences), rabbit anti-
Giantin (ab24586, Abcam), rabbit anti-tGolgin-1/GOLGA4
(kindly provided by Dr Mickey Marks, University of Pennsylva-
nia), rabbit anti-sortilin (ab16640, Abcam), rabbit anti-SorLA
(ab16642, Abcam), mouse anti-CI-M6PR (clone 2G11,
Abcam), rabbit anti-cathepsin D (Santa Cruz Biotech), rabbit
anti-Iba1 (Wako), rabbit anti-GFAP (Z0334, Dako), mouse anti-
phosphorylated neurofilament H (clone SMI-31, Covance),
mouse anti-phosphorylated neurofilament M/H (clone SMI-312,
Covance), mouse anti-synaptophysin 1 (clone 7.2, Synaptic
Systems), guinea pig anti-p62 (GP62, Progen Biotech), mouse
anti-APP (clone 22C11, Millipore), mouse anti-Tau (clone
TAU-5, Invitrogen), mouse anti-PHF-1 (kindly provided by Dr
Peter Davies, Albert Einstein College of Medicine). For bright-
field microscopy, biotinylated secondary antibodies used were
goat anti-mouse, anti-rabbit or anti-guinea pig (Vector Laborator-
ies) followed by ABC reagent and DAB Peroxidase Substrate
(Vector Laboratories). For fluorescence confocal imaging, sec-
ondary antibodies used were: AlexaFluor-488, -546, or -633
goat anti-mouse IgG (H+ L), and AlexaFluor-488, -546 or
-633 goat anti-rabbit IgG (H+ L) (Life Technologies). Second-
ary antibodies used were: HRP- or biotin-conjugated mouse
monoclonal anti-rabbit IgG, light chain-specific (Jackson Immu-
noresearch), goat anti-mouse IgG, light chain-specific (Jackson
Immunoresearch) and goat polyclonal anti-guinea pig IgG, H +
L (Abcam).
Yeast growth assays
Human VPS35 variants (WT, D620N or P316S) were amplified
by PCR from a pLenti6-VPS35 vector (Addgene #21691), and
yeast VPS35 variants (WT, D686N or P299S) were amplified
by PCR from a pBG1805-VPS35 vector containing a C-terminal
HA tag (Thermo Scientific). Blunt-end PCR products were
cloned into a directional pENTR/D-TOPO entry vector,
sequenced to confirm their integrity, and subjected to recombin-
ation with the Gateway-compatible vector, p416GAL1-ccdB
(CEN6, URA3) obtained from Addgene (31). Yeast haploid
WT parental or vps35D strains on a BY4741 genetic background
(MATa, his3D1, leu2D0,met15D0, ura3D0) were obtained from
Thermo Scientific. Yeast cells were transformed with plasmids
using a standard lithium acetate procedure. Yeast cells trans-
formed with p416GAL1 expression plasmids were routinely
grown in complete synthetic media lacking uracil (CSM-URA)
with 2% dextrose. Equivalent yeast cells were serially diluted
(5-fold) and spotted onto plates containing solid media (YP or
CSM-URA) with 2% dextrose, galactose, glycerol or ethanol
as the sole carbon source. Cells were grown at 308C for 2–3
days before imaging.
Lentivirus production
Lentiviral vectors were produced as described (32) in
HEK-293T cells using a third generation packaging system.
Lentivirus was purified by centrifugation and resuspended in
1× phosphate buffered saline pH 7.4 and 0.5% bovine serum
albumin buffer. Viral titer was determined using the HIV-1
p24 antigen ELISA kit (Zeptometrix Corp, Buffalo, USA). A
p24 of 66 ng/ml was routinely used for infecting primary neuron-
al cultures at a density of 400 000 cells in 3 ml media.
Cell culture and transfection
HEK-293T cells were grown in Dulbecco’s modified Eagle’s
media (DMEM) supplemented with 10% fetal bovine serum
(FBS) and addition of penicillin/streptomycin in a humidified
Figure 9. Nigral axonal degeneration induced by AAV2/6-mediated expression of D620N VPS35. Representative photomicrographs of substantia nigra sections pro-
cessedwith Gallyas silver stain, from rats injected with AAV2/6vectors expressinghumanVPS35WT and VPS35D620N or a control vector, to reveal degenerating axons
and nerve terminals (indicated in black). Scale bar: 50 mm. Images were subjected to deconvolution, color separation and filtering (circularity index ≤0.6 to remove
nuclei/soma) using ImageJ to isolate black particles representative of neuritic processes and terminals for quantitation. Examples of particles analyzed are shown
pseudocolored in red. Data are expressed as the number of black particles (silver-positive neurites/terminals) and bars represent the mean+SEM (n ¼ 6 animals/
group). ∗∗P,0.01 or ∗∗∗P,0.001 by one-way ANOVA with Tukey’s post hoc analysis as indicated. n.s., non-significant.
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378C incubator with 5% CO2. Primary human fibroblasts were
maintained in DMEM supplemented with 10% FBS, 2 mM
L-glutamine and penicillin/streptomycin. Expression plasmids
were transfected into cells using XtremeGENE HP DNA trans-
fection reagent (Roche Applied Science) or Lipofectamine
2000 (Life Technologies) according to manufacturer’s instruc-
tions. Biochemical or immunocytochemical analysis was per-
formed at 48–72 h post-transfection.
Human primary fibroblasts
Fibroblasts were generated from a 6 mm skin punch biopsy taken
under local anesthetic following local ethics board approval and
informed consent from the patient. Biopsies were dissected into
1 mm pieces and cultured in 5 cm2 petri dishes in media until
fibroblasts grew out from the explants. When fibroblasts
reached confluency they were transferred to larger culture
vessels for expansion. Fibroblasts were generated from a
single normal control individual and a PD subject harboring a
c.1858G.A, p.Asp620Asn mutation in the VPS35 gene, as
described (33).
Immunocytochemistry
Primary neurons or fibroblasts were fixed in 4% paraformalde-
hyde (PFA) and processed for immunocytochemistry as previ-
ously described (32). Images were captured with a Zeiss LSM
700 laser scanning confocal microscope (Carl Zeiss AG) with
a Plan-Apochromat 63×/1.40 oil objective. Acquired images
from single z-plane (0.1-mm thick) were subjected to deconvolu-
tion with HuygensPro software (Scientific Volume Imaging).
Co-localization coefficients (Rcoloc) of deconvolved multi-
channel images were calculated using NIH ImageJ software as
previously described (32).
Neuronal viability and neurite length assays
Primary cortical neuronal cultures were prepared from P1
Sprague-Dawley rats as previously described (32,34). For assess-
ment of neurite length, cultures were co-transfected at DIV 3 with
V5-tagged human VPS35 and GFP plasmids at a 10:1 DNA molar
ratio (5 mg total DNA per 35 mm dish) using Lipofectamine 2000
reagent (Invitrogen). Cultures were fixed with 4% PFA at DIV 7
and immunostained with mouse anti-V5 antibody (Invitrogen),
and anti-mouse IgG-AlexaFluor-633 antibody (Invitrogen).
Images were acquired using an EVOS fluorescence digital
microscope (Advanced Microscopy Group). ImageJ software
was used to measure the length of the longest neurite from
control (GFP-positive) and VPS35-expressing (GFP-/V5-posi-
tive) neurons. Sampling was performed randomly with ≥30
neurons measured per condition for each experiment from 4–6 in-
dependent cultures/experiments. All measurements were per-
formed by investigators blinded to experimental condition.
TUNEL labeling was performed as previously described (32) to
assess apoptotic cell death in cortical neurons infected with lenti-
viral vectors expressing V5-tagged VPS35 or GFP at DIV 3 and
fixed with 4% PFA at DIV 14. Cell viability was also assessed fol-
lowing treatment of lentiviral-infected cortical neurons seeded in
96-well plates with cellular toxins for 24 h using the alamarBlue
Cell Viability assay (Invitrogen).
Subcellular fractionation
Cerebral cortex from adult mice (C57Bl/6J) was subjected to
subcellular fractionation as previously described (32). The fol-
lowing fractions were obtained: total homogenate (H) and
nuclear/whole cell pellet (P1), soluble cytosolic (S1, S2 and
S3), heavy membrane (P2), light membrane/microsomal (P3),
synaptosomal membrane (LP1) and cytosolic (LS1), synaptic
vesicle-enriched membrane (LP2) and cytosolic (LS2).
Human brain tissue
For immunohistochemical analysis, postmortem human brain
tissue was obtained through the brain donation program of the
Morris K. Udall Parkinson’s Disease Research Center of Excel-
lence and the Alzheimer’s Disease Research Center at Johns
Hopkins Medical Institutions (JHMI) in compliance with local
Institutional Review Board and HIPAA regulations. Formalin-
fixed, paraffin-embedded tissue sections (10-mm thick) contain-
ing cingulate cortex tissue from two normal control and four PD/
DLB brains was obtained as indicated in Table 1 and described
previously (34). For biochemical analysis, caudate putamen
tissue derived from five normal control and seven PD/DLB sub-
jects was obtained from JHMI (Table 1), and frontal cortex tissue
derived from four normal control and eight PD subjects was
obtained from the archive at Queen Square Brain Bank
(QSBB) as previously reported (35) and indicated in Table 2.
Flash-frozen tissues were homogenized with (10% w/v) lysis
buffer [20 mM Tris–HCl pH 7.4, 150 mM NaCl, Complete pro-
tease inhibitor and phosphatase inhibitor cocktails (Roche
Applied Science)] and equal proteins were resolved by 3–8%
Tris–acetate sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) (Invitrogen). Blots were probed with
anti-VPS35, anti-actin or anti-b-tubulin antibodies.
Recombinant AAV2/6 virus production
V5-tagged human VPS35 (WT or D620N) cDNAs were ampli-
fied by PCR from a pLenti6-VPS35 vector and cloned into a
pAAV-mPGK-MCS vector (16), modified from the serotype 2
pAAV-CMV-MCS vector (Stratagene, La Jolla, CA, USA).
The same backbone plasmid was used to produce the non-
expressing control virus. Recombinant AAV2 genome packaged
in the AAV serotype six capsid was produced and titrated as
described previously (16,36). Viruses were diluted to a final con-
centration of 2.5 × 109 transducing units (TU) per ml.
Stereotactic surgeries
Female adult Sprague-Dawley rats (Charles River Laboratories,
France) weighing 180–200 g received a viral titer of 5 × 106
TUs (in a 2 ml volume), unilaterally, at coordinates correspond-
ing to the rat substantia nigra, as previously described (36).
Animals were sacrificed at 12 weeks postsurgery.
Biochemical analysis of cell culture and tissues
Cells or brains were homogenized with lysis buffer containing
1% Triton X-100, 50 mM Tris–HCl pH 7.5, 150 mM NaCl,
5% glycerol, 1 mM EDTA, Complete protease inhibitors
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(Roche Applied Sciences) and phosphatase inhibitor cocktails 2
and 3 (Sigma). Rat tissues for biochemical analysis were har-
vested at 12 weeks after viral delivery (n ¼ 4 animals/group).
Ventral midbrains from injected and non-injected hemispheres
were rapidly dissected and subjected to mechanical homogen-
ization with (10% w/v) lysis buffer. Cell and tissue lysates
were centrifuged at 100 000g for 30 min at 48C. To obtain the in-
soluble fraction, Triton X-100-insoluble pellets from fibroblasts
were solubilized in buffer containing 2% SDS, 50 mM Tris–HCl
pH 7.4 and Complete protease inhibitors (Roche). Equivalent
proteins as determined by BCA assay (Pierce Biotechnology)
were resolved by SDS-PAGE and subjected to western blot ana-
lysis with appropriate primary and secondary antibodies. Pro-
teins were visualized by enhanced chemiluminescence (GE
Healthcare) and digital images were captured using a chemilu-
minescent Image Analysis system (LAS-4000, FujiFilm).
Acquired images were subjected to densitometric quantitation
using NIH ImageJ software. The relative optical density values
for each protein band were normalized to the corresponding
levels of b-tubulin, actin or PGK proteins to control for protein
loading.
Immunohistochemistry
Animals were deeply anesthetized and transcardially perfused
with saline solution followed by 4% PFA in 0.1 M phosphate
buffer (pH 7.3). Brains were immersed in 30% sucrose solution
before sectioning using a cryostat (Leica, Jung Frigocut 2800N).
Immunohistochemistry on rat and human brain tissue with
various antibodies was conducted as described previously
(34,37). Silver staining was performed using the FD NeuroSilver
kit II following the manufacturer’s protocol (FD Neurotechnol-
ogies, Ellicott City, MD). Images were captured with the light
microscopes AX70 and Slide Scanner VS120-L100 (Olympus)
or a Zeiss LSM 700 Laser Scanning confocal microscope (Carl
Zeiss AG).
Cylinder test
The forelimb usage of rats was assessed by placing each animal
into a transparent cylinder and recording the exploratory activity
for 5 min. The contact of either left or right forelimbs with the
cylinder wall, while the animals were in a vertical posture, to
support body weight or to initiate lateral stepping movements
was scored in a manner blinded to experimental group. Forelimb
use asymmetry was quantified by calculating the instances when
the impaired (contralateral) forelimb was used as a percentage of
total number of both limb usages on the cylinder wall.
Stereological quantitation of neurons
Unbiased stereological estimation of the number of dopamin-
ergic neurons was performed using the optical fractionator
probe of the StereoInvestigator software (MicroBrightField
Biosciences), as described (37,38). Every fifth serial coronal
section of 40 mm thickness, covering the entire substantia
nigra region was immunostained with rabbit anti-TH antibody
and counterstained with cresyl violet stain. Sampling was per-
formed in a systematic random manner using a grid of 220 ×
240 mm squares covering the substantia nigra overlayed on
each section and applying an optical dissector consisting of a
75 × 75 × 20 mm square cuboid. All analyses were performed
by investigators blinded to each condition.
The optical density of TH-immunoreactive nerve terminals
was quantified throughout the striatum as a measure of dopamin-
ergic innervation. The rostral and caudal limits of the striatum
used for analysis were 2.00 to 20.50 mm relative to bregma,
and every 10th serial section within this region was examined.
Following immunolabeling with anti-TH antibody, sections
were scanned at 4× magnification using a virtual slide micro-
scope scanning system (VS110, Olympus) and quantified
using NIH ImageJ software.
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